Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study

Franck Morschhauser (1) , Kamal Bouabdallah (2) , Stephan Stilgenbauer (3) , Catherine Thieblemont (4) , Sophie de Guibert (5) , Florian Zettl (6) , Lawrence M Gelbert (7) , P Kellie Turner (8) , Siva Rama Prasad Kambhampati (8) , Li Li (8) , Lily Q Li (8) , Sean Buchanan (8) , Susana Barriga (8) , Melissa M Bear (8) , Martin Wilhelm (9) , Georg Hess (10)

1 Hôpital Claude Huriez [Lille]
2 CHU Bordeaux
3 Universität Ulm - Ulm University [Ulm, Allemagne]
4 AP-HP - Hopital Saint-Louis [AP-HP]
5 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
6 Georg-August-University = Georg-August-Universität Göttingen
7 LMG PharmaTech
8 Eli Lilly and Company [Indianapolis]
9 Klinikum Nürnberg Nord
10 JGU - Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University

Mots clés: Abemaciclib; CDK4 and 6 inhibitor; Mantle cell lymphoma; non-Hodgkin lymphoma

Domaines: Sciences du Vivant [q-bio]; Hématologie

Franck Morschhauser, Kamal Bouabdallah, Stephan Stilgenbauer, Catherine Thieblemont, Sophie de Guibert, et al.. Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. Haematologica, 2020, ⟨10.3324/haematol.2019.224535⟩. ⟨hal-02635130⟩